Elicio Therapeutics (ELTX) News
NASDAQ: ELTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.45-0.05 (-3.33%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ELTX news summary
We found 3 recent headlines mentioning Elicio Therapeutics (ELTX): 0 in the past week and 2 in the past 30 days, most often from GlobeNewswire. For price context, ELTX is down 3.33% at $1.45. The most recent story, "Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update", was published by GlobeNewswire on Nov 5, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Elicio Therapeutics headlines
- Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateBOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…GlobeNewswire
- Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual MeetingBOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…GlobeNewswire
- Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature MedicineBOSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…GlobeNewswire